Skip to main content
Premium Trial:

Request an Annual Quote

Exosome Diagnostics Raises $6.5M

NEW YORK (GenomeWeb News) – Exosome Diagnostics said in a regulatory filing that it has raised $6.5 million toward a targeted $8 million financing round.

In a Form D/A filed with the US Securities and Exchange Commission, the New York-based firm said the types of securities offered included debt; options, warrants, and other rights to acquire other securities; and securities to be acquired upon the exercise of options, warrants, and other rights to acquire securities.

The firm did not disclose in the filing its investors in the round or how proceeds would be used. Through a spokesman, Exosome declined to confirm the raise or to comment.

In February, the firm said in an SEC document that it had raised $5 million of a targeted $6 million raise. It is unclear whether the current raise includes the February amount.

Three years ago, Exosome raised $20 million.

The company, founded in 2008, develops biofluid-based molecular diagnostic tests based on proprietary exosome technology licensed from Massachusetts General Hospital. The core technology applies to exosomes, lipid microvesicles containing nucleic acids and other molecules shed into body fluids, as Clinical Sequencing News reported last year.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.